Development and validation of an oxidative stress—associated prognostic risk model for melanoma

Yu Yang¹, Xuan Long², Kun Li³, Guiyun Li³, Xiaohong Yu¹, Ping Wen², Jun Luo³, Xiaobin Tian⁴ and Jinmin Zhao¹

¹ Department of Orthopedics Trauma and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
² Department of Obstetrics and Gynecology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
³ The Second People’s Hospital of Guiyang, Guiyang, China
⁴ Guizhou Medical University, Guiyang, China

ABSTRACT

Background. Oxidative stress (OS) is key to various diseases and is implicated in cancer progression and oncogenesis. However, the potential diagnostic value of OS-related genes in skin cutaneous melanoma (SKCM) remains unclear.

Methods. We used data of RNA sequencing from 471 tumor tissues and one healthy tissue acquired from The Cancer Genome Atlas (TCGA)-SKCM cohort. The Genome Tissue Expression database was used to acquire transcriptome data from 812 healthy samples. OS-related genes that were differentially expressed between SKCM and healthy samples were investigated and 16 prognosis-associated OS genes were identified. The prognostic risk model was built using univariate and Cox multivariate regressions. The prognostic value of the hub genes was validated in the GSE65904 cohort, which included 214 SKCM patients.

Results. The overall survival rate of SKCM patients in the high-risk group was decreased compared to the low-risk group. In both TCGA and GSE65904 cohorts, the ROC curves suggested that our prognostic risk model was more accurate than other clinicopathological characteristics to diagnose SKCM. Moreover, risk score and nomograms associated with the expression of hub genes were developed. These presented reiterated our prognostic risk model. Altogether, this study provides novel insights with regards to the pathogenesis of SKCM. The 16 hub genes identified may help in SKCM prognosis and individualized clinical treatment.

INTRODUCTION

Skin cutaneous melanoma (SKCM) is an aggressive cancer that has been recognized as a relevant cause of death (Ekwueme et al., 2011). Indeed, SKCM is the most frequent cause of death in patients with skin tumors (Holmes, 2014; Liu-Smith, Jia & Zheng, 2017). Early diagnosis and treatment of SKCM are crucial for a favorable prognosis (Hamm et al., 2008); however its pathogenesis remains unclear. Previous studies showed that the degree
of skin pigmentation is associated with the progression and occurrence of SKCM (PDQATE Board, 2002; Kanavy & Gerstenblith, 2011). Genetic susceptibility, acquired melanocytic nevi, and family history also play key roles in disease pathogenesis (Gilchrest et al., 1999; Hawkes, Truong & Meyer, 2016). However, it is often difficult to use the above factors to facilitate early diagnosis, making the development of better tools to diagnose early SKCM an important objective in the field (Eisenstein et al., 2018). Therefore, understanding the molecular mechanisms of SKCM and exploiting effective early diagnosis indicators may have a great impact on the survival rate and long-term quality of life of SKCM patients.

The occurrence of oxidative stress (OS) is due to the unbalance between cellular oxidant and antioxidant systems due to various internal and external factors that ultimately lead to the generation of reactive oxygen species (ROS). These are comprised of reactive nonradical species and free radicals, e.g., singlet oxygen, superoxide anion, and hydrogen peroxide (Lü et al., 2010). Excessive ROS can lead to double-stranded DNA breaks and genotoxicity, eventually leading to genomic mutations and tumorigenesis (Moloney & Cotter, 2018; Wang et al., 2017; Zhou, Shen & Claret, 2013). The expression of OS genes plays a crucial role in physiological homeostasis and is associated with the development and progression of several human diseases, such as osteoporosis (Almeida & Porter, 2019), neurodegenerative (Buendia et al., 2016), and inflammatory diseases (Thomson, Hemphill & Jeejeebhoy, 1998). However, both the molecular association between OS genes and SKCM, and their impact on early prognosis, are poorly understood.

Previous studies have described the relationship between OS and its effects on tumorigenesis and disease progression of different tumors (Gill, Piskounova & Morrison, 2016; Klaunig, 2018). For example, in oral squamous cell carcinoma, differential expression of OS-related genes provides a potential basis for clinical drug treatment and clinical decision-making (Pedro et al., 2018). In SKCM patients, the concentration of ROS is reported to be elevated (Liu-Smith, Dellinger & Meyskens, 2014), yet only a few potential mechanisms underlying the roles of OS genes in SKCM have been evaluated. To our knowledge, no systematic study has investigated if OS hub genes are correlated with the prognosis or progression of SKCM. In our study, we obtained the expression profiles of healthy skin and SKCM samples from The Cancer Genome Atlas (TCGA) and the Genome Tissue Expression (GTEx) databases to investigate hub genes related to SKCM prognosis. Subsequently, a prognostic risk model was constructed using the identified OS-related genes and the clinical significance and function of each OS gene in SKCM were systematically explored.

MATERIALS AND METHODS

Processing of raw data

RNA sequencing samples from 472 individuals were obtained from the TCGA database, which comprised of 471 SKCM samples and one healthy skin tissue sample (https://portal.gdc.cancer.gov/). In addition, to increase the number of healthy samples, we collected 812 RNA sequencing data from healthy skin tissues obtained from the GTEx database (https://gtexportal.org/home/datasets) (Human Genomics, 2015; Gentles et al.,
A total of 1399 OS-related genes with relevance score ≥ 7 were collected from the Gene Cards database (https://www.genecards.org). Under \( \log_2 \) fold change≥ 2 and a standard false discovery rate (FDR) <0.05, an R package was used to detect genes differentially expressed in SKCM and healthy skin samples (Li et al., 2020). Meanwhile, an average count cutoff of 1 was used to eliminate genes. After univariate and multivariate Cox analyses, 16 OS-related genes associated with SKCM prognosis were obtained for the construction of the risk model. We used the National Center for Biotechnology Information-Gene Expression Omnibus database to download the GSE65904 dataset, a cohort of 214 SKCM patients for external verification. The basic characteristics of these SKCM samples were all displayed in Table 1.

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and Gene Ontology (GO)

KEGG enrichment analysis and GO of OS-associated differentially expressed genes (DEGs) were performed to assess their biological functions. The Database for Annotation, Visualization, and Integrated Discovery 6.8 (Huang, Sherman & Lempicki, 2009) was used to perform the analyses.

Establishing protein-protein interaction (PPI) network and screening for important modules

PPI information from OS-associated DEGs was acquired from the STRING platform (http://www.string-db.org/) (Szklarczyk et al., 2019). The PPI network was developed using Cytoscape 3.7.0. The virtual modules and hub genes in the PPI network with a Molecular Complex Detection (MCODE) score and node count >5 \( (p < 0.05) \) were selected using the MCODE plug-in (Bader & Hogue, 2003).

Construction of a prognostic risk model

The univariate Cox regression of hub genes found in the PPI network was performed using the ‘survival’ R package. Subsequently, multivariate Cox regression was used to further analyze the above OS-related genes and select genes to build the prognostic risk model. We calculated the risk value of patients with SKCM based on the expression and coefficient values of 16 OS genes and classified them into high- and low-risk queues through the median risk score. The risk score was determined according to the equation below:

\[
\text{Risk score} = \sum \text{expgenei} \times \beta_i,
\]

where expgenei is the expression level of 16 OS-associated genes and \( \beta \) is the coefficient value for the gene. Receiver operating characteristic (ROC) curves were generated using the ‘timeROC’ and ‘survivalROC’ packages for R and were applied to assess the accuracy of our risk model to predict the overall survival rate of SKCM patients. Separate nomograms were constructed based on clinical characteristics and the 16 OS genes. The calibration chart was used to detect the predictive power of the above nomograms (one based on clinical characteristics and one based on the 16 OS genes) for the overall survival time of SKCM patients. To validate the prognostic performance of the constructed risk model, the analyses described above were conducted using data from the GSE65904 cohort.
Table 1  Basic characteristics of the clinical variables in SKCM patients.

| Clinical variables | TCGA cohort | Clinical variables | GSE65904 cohort |
|--------------------|-------------|--------------------|-----------------|
| Survival status    |             | Survival status    |                 |
| Dead               | 224         | Dead               | 102             |
| Survived           | 239         | Survived           | 108             |
| Unknown            |             | Unknown            | 4               |
| Median age (year)  | 57.84       | Median age (year)  | 62.35           |
| Sex                |             | Sex                |                 |
| Female             | 174         | Female             | 89              |
| Male               | 289         | Male               | 124             |
| Unknown            |             | Unknown            | 1               |
| T stage            |             | Tumor stage        |                 |
| 0                  | 23          | General            | 23              |
| 1                  | 42          | In-transit         | 15              |
| 2                  | 77          | Local              | 11              |
| 3                  | 91          | Primary            | 16              |
| 4                  | 150         | Regional           | 139             |
| Unknown            | 80          | Unknown            | 10              |
| N stage            |             | Tissue             |                 |
| 0                  | 227         | Cutaneous          | 22              |
| 1                  | 75          | Lymph node         | 130             |
| 2                  | 50          | Subcutaneous       | 33              |
| 3                  | 57          | Visceral           | 10              |
| Unknown            | 54          | Unknown            | 19              |
| M stage            |             | Metastatic status  |                 |
| 0                  | 411         | Metastatic         | 361             |
| 1                  | 24          | Primary            | 99              |
| Unknown            | 28          | Others             | 3               |

Validation of expression levels and prognostic values of hub genes

After clarifying the translational expression level of hub genes in the TCGA cohort, we verified the differential expression of 16 OS genes between SKCM and normal skin tissues using data from the Human Protein Atlas (HPA) (Thul et al., 2017). In the TCGA cohort,
Identification of OS-associated DEGs

Figure 1A shows the workflow of the study. In total, 1399 OS genes were selected to study their differential expression in SKCM and healthy tissues. Of these, 156 were identified as OS-associated DEGs (63 upregulated and 93 downregulated genes) in SKCM (Fig. 1B).

Functional enrichment analysis of OS-associated DEGs

We used the KEGG pathway analysis to analyze the DEGs and found that upregulated genes were mostly correlated with cytokin-cytokin receptor interaction and human T-cell leukemia virus 1 infection (Fig. 2A), while downregulated genes were predominantly linked with fluid shear stress and atherosclerosis (Fig. 2B). GO analysis was also performed to further explore the DEGs. As a result, with regard to biological processes, upregulated DEGs were significantly augmented in leukocyte migration and leukocyte chemotaxis (Fig. 3A), whereas DEGs that were downregulated were mainly augmented in response to OS and cellulaire response to OS (Fig. 3B). With regard to cell location, upregulated genes were mainly augmented on the external side of plasma membrane and secretory granule membrance (Fig. 3A). Downregulated genes were enriched in the vesicle lumen and cytoplasmic vesicle lumen (Fig. 3B). Finally, it was evident that upregulated OS genes were concentrated in cytokine activity and cytokine receptor binding (Fig. 3A), while downregulated OS genes were mostly implicated in antioxidant activity and heme binding (Fig. 3B).
Creation of a PPI network for OS-associated DEGs and screening of key modules

To further explore the inner relationship of OS-associated DEGs, a PPI network was established with 144 nodes and 834 edges (Fig. 4A). The most meaningful module with 19 nodes and 158 edges was subsequently identified (Fig. 4B). OS-related genes within the key module were primarily involved in chemokine-mediated signaling transduction, leukocyte migration, response to chemokine, and chemokine signaling pathway.

Screening of hub genes and construction of a prognostic risk model

A total of 144 OS-associated DEGs were identified from the PPI network. After univariate Cox regressions, 61 OS genes were identified as genes of prognostic value in SKCM patients (Fig. 5A). The multivariate Cox regression model helped to select 16 hub genes (CDK2, CCR5, NDUFA9, NDUFA13, HLA.DRB1, CXCR3, FOXM1, CCL4, ISG15, FCGR2A, FCGR3A, PIK3R2, SLPI, SELL, PSEN2, and GJA1) that were used to calculate the prognostic risk model (Fig. 5B, Table 2).

Validation of the prognostic value of the risk model

The median risk score of the prognostic risk model was used to separate SKCM patients in the TCGA and GSE65904 cohorts into high- and low-risk queues (Figs. 6A, 6B). The survival time of SKCM patients in the high-risk group was significantly lower when compared to the low-risk group (Figs. 6C, 6D). A ROC curve was constructed to validate the accuracy
Figure 3  GO enrichment analysis of OS-associated DEGs. (A) Top 10 classes of GO enrichment terms about up-regulated DEGs in biological process (BP), cellular component (CC), and molecular function (MF). (B) Top 10 classes of GO enrichment terms about down-regulated DEGs in BP, CC, and MF.

Figure 4  PPI network and modules screening. (A) PPI network of OS-associated DEGs. (B) Critical module from PPI network. Green circles represent down-regulated genes, and red circles represent up-regulated genes.
Figure 5  Identification of hub OS genes in TCGA cohort. (A) Univariate Cox regression analysis for identification prognosis-associated OS genes. (B) Multivariate Cox proportional hazards regression model was constructed based on the identified prognostic-related OS genes.

Table 2  Sixteen prognosis-associated hub OS genes identified by multivariate Cox regression analysis.

| Symbol  | coef   | HR     | Lower 95% CI  | High 95% CI   | P-value |
|---------|--------|--------|---------------|---------------|---------|
| CDK2    | 0.0993 | 1.1044 | 0.9682        | 1.2597        | 0.1393  |
| CCR5    | 0.5314 | 1.7014 | 1.1290        | 2.5638        | 0.0111  |
| NDUFA9  | -0.4646| 0.6284 | 0.4083        | 0.9672        | 0.0347  |
| NDUFA13 | 0.4240 | 1.5280 | 1.1096        | 2.1042        | 0.0094  |
| HLA.DRB1| -0.2531| 0.7764 | 0.6477        | 0.9307        | 0.0062  |
| CXCR3   | -0.3069| 0.7358 | 0.5371        | 1.0080        | 0.0561  |
| FOXM1   | 0.3925 | 1.4807 | 1.2259        | 1.7883        | 0.0000  |
| CCL4    | -0.3873| 0.6789 | 0.5224        | 0.8823        | 0.0038  |
| ISG15   | -0.1498| 0.8609 | 0.7684        | 0.9645        | 0.0098  |
| FCGR2A  | -0.1357| 0.8731 | 0.7509        | 1.0152        | 0.0777  |
| FCGR3A  | 0.2993 | 1.3489 | 1.0747        | 1.6931        | 0.0098  |
| PIK3R2  | 0.6541 | 1.9234 | 1.1688        | 3.1653        | 0.0101  |
| SLPI    | 0.1903 | 1.2096 | 1.1106        | 1.3174        | 0.0000  |
| SELL    | 0.2599 | 1.2968 | 1.1058        | 1.5208        | 0.0014  |
| PSEN2   | 0.2011 | 1.2228 | 1.0143        | 1.4741        | 0.0349  |
| GJA1    | 0.1313 | 1.1403 | 1.0096        | 1.2879        | 0.0345  |
Figure 6  Construction of prognostic model in the TCGA and GSE65904 cohort.  (A) Risk score distribution, survival status, and expression heat map of TCGA cohort. (B) Risk score distribution, survival status, and expression heat map of GSE cohort. (C) Survival curve of TCGA cohort. (D) Survival curve of GSE cohort. (E) ROC curves for forecasting overall survival in TCGA cohort. (F) ROC curves for forecasting overall survival in GSE cohort.
of our risk model. It indicated that our risk model had a moderate predictive effect using data from the TCGA cohort (area under the ROC curve [AUC] of 1-year survival = 0.742; 3-year survival = 0.723; and 5-year survival = 0.764) (Fig. 6E). Similarly, both the prognostic effect and accuracy were validated in the GSE65904 cohort, in which the AUC of 3-year survival was 0.705 (Fig. 6F). The univariate and multivariate Cox regressions of different clinical characteristics of SKCM patients in the TCGA cohort showed that the gene-based risk score was a robust prognostic parameter for SKCM patients (Figs. 7A, 7B). When compared with other clinical features in the TCGA and GSE65904 cohort, our prognostic risk model showed a better prognostic performance in all AUCs (Figs. 7C–7H), revealing that our gene-based prognostic risk model displayed moderate specificity and sensitivity with regard to predicting SKCM prognosis. The correlation analysis between clinical parameters and risk score indicated that SKCM patients in the T3 and T4 stages or those with primary cancer had a higher risk score. (Figs. 7I, 7J). A heatmap was drawn to show the correlation between the levels of 16 OS genes in the TCGA and GSE65904 cohorts against different clinical parameters, including high- and low-risk groups, TNM stage, age, and gender (Fig. 7K, 7L).

Furthermore, in the TCGA and GSE65904 cohorts, the nomograms of our risk score and different clinical parameters were constructed to predict the overall prognosis of SKCM patients (Fig. 8A, 7B). In parallel, the calibration diagram evidenced that the above nomograms had a good predictive effect on the clinical outcome of SKCM patients (Figs. 8C–8F).

Validating the prognostic value and expression levels of hub genes

In SKCM samples, the expression levels of CDK2, CCR5, HLA-DRB1, CXCR3, FOXM1, CCL4, ISG15, FCGR2A, FCGR3A, SELL, and PSEN2 were considerably increased, while the levels of NDUFA9, NDUFA13, PIK3R2, SLPI, and GJA1 were markedly decreased when compared with that in healthy samples (File S1A). These results were validated by immunohistochemistry analysis from the HPA database (File S1B).

To visualize the interactions between hub DEGs, we constructed a PPI network using the STRING database online tool (Fig. 9A). The genes FCGR2A and CCR5 showed the highest interacting degrees among the hub genes (Fig. 9B). The KM method showed that a high expression level of HLA-DRB1, CXCR3, CCL4, ISG15, FCGR2A, FCGR3A, SELL, and CCR5 were correlated with a significant increase in the overall survival rate in SKCM, whereas a high expression level of PSEN2, CDK2, FOXM1, GJA1, NDUFA9, NDUFA13, PIK3R2, and SLPI were correlated with a significant decrease of the overall survival rate (File S2). Moreover, as shown in File S3, the genes SELL, PSNE2, FOXM1, CDK2, and HDUFA9 were all significantly related to with SKCM ages, while genes HDUFA13 and CCL4 were significantly connected the ganders of SKCM patients. For the TCGA and GSE65904 cohorts, we also constructed the nomograms related to the 16 OS genes to predict the 1-, 3-, and 5-year survival probability of SKCM patients (File S4). The calibration of the nomograms associated with the 16 OS genes presented good consistency between the predicted and observed outcomes.
Figure 7  Efficacy evaluation of constructed prognostic model. Univariate (A) and multivariate (B) Cox regression analysis of the clinicopathological features in TCGA cohort. ROC curves for forecasting overall survival in TCGA (C-E) and GSE65904 (F-H) cohort. (I) The relationship between the risk scores and T stage in TCGA cohort. (J) The relationship between the risk scores and metastatic ability in TCGA cohort. The heatmap shows the distribution of clinicopathological features and OS genes expression in TCGA (K) and GSE65904 (L) cohort.
DISCUSSION

The incidence of SKCM has increased over the past 50 years, and it ranks 19th among the most common malignant tumors worldwide (Holmes, 2014). Currently, the management of SKCM is through surgical resection, although it does not sufficiently improve the overall survival rate (Swetter et al., 2019). OS is known to be involved in the occurrence and development of several tumors (Kruk & Aboul-Enein, 2017), however the prognostic value of OS genes on tumor survival remains unclear. Here, we sought to identify molecular
biomarkers to predict the prognosis of SKCM and provide a rationale for decisions regarding treatment. Therefore, we analyzed the differential expression of OS-related genes between SKCM and normal samples, obtaining 156 DEGs (63 upregulated and 93 downregulated genes). GO enrichment analysis indicated that DEGs were mainly involved in OS, chemokine, and ROS-associated functions, whereas KEGG pathway analysis suggested that they could have a significant impact on the initiation and growth of certain tumors, such as prostate cancer, hepatocellular carcinoma, pancreatic cancer, bladder cancer, and especially melanoma.

A PPI network was built to analyze the interactions between OS-associated DEGs and identify a key module. Furthermore, univariate and multivariate Cox regressions revealed 16 hub genes, including HLA-DRB1, CXCR3, CCL4, ISG15, FCGR2A, FCGR3A, SELL, CCR5, PSEN2, CDK2, FOXM1, GJA1, NDUFA9, NDUFA13, PIK3R2, and SLPI. Interestingly, these genes were found to have several cancer-related roles: CXCR3 can interact with LRP1 leading to ligand-induced conformational changes on the cell membrane, which results in increased tumor cell migration (Boyé et al., 2017); ISG15 is highly expressed in hepatocellular carcinoma tissues and interacts with XIAP to drive proliferation and metastasis (Li et al., 2014; Tong et al., 2020); CCR5 is positively associated with the size of the primary tumor (Suarez-Carmona et al., 2019), whereas its overexpression significantly promotes leukocyte accumulation, angiogenesis, and tumor progression in oral squamous cell carcinoma (Da Silva et al., 2017); NDUFA9 is related to colitis-associated cancer and may be connected with the activation of the LKB1/AMPK pathway in colorectal epithelial cells (Wang, Cui & Qu, 2019); PIK3R2 is closely related to liver cancer prognosis, since its overexpression significantly increases the probability of liver cancer metastasis and angiogenesis (Du et al., 2014); and SLPI provides a local immune response to human papillomavirus infection in the cervical mucosa (Sahin et al., 2018), while its modulation significantly inhibits the expression of apoptosis-associated genes, promoting the proliferation and metastasis of gastric cancer (Du et al., 2017; Sahin et al., 2018). Although the modulation effects of these genes had been explored in various tumors, few studies have systematically analyzed their specific prognostic values in SKCM.

In the present study, the survival analysis results obtained through the KM method showed that the expression levels of 16 OS-related genes were associated with SKCM patients’ survival. Elevated expression of PSEN2, CDK2, FOXM1, GJA1, NDUFA9, NDUFA13, PIK3R2, and SLPI was associated with a lower survival rate, indicating that these genes may be oncogenes. Conversely, overexpression of HLA-DRB1, CXCR3, CCL4, ISG15, FCGR2A, FCGR3A, SELL, and CCR5 was associated with a significantly higher survival rate, revealing their vital role in inhibiting the progression of cancer.

The ROC curves and survival analyses confirmed the advanced biological implications of our model to predict the outcomes of SKCM patients. In addition, it showed an improved predictive accuracy when compared to other clinical parameters. Cox regressions evidenced that our risk score was an independent prognostic parameter for SKCM patients. Nomograms constructed based on the gene expression levels and risk signature ascertained the credibility of our risk model to estimate the overall survival time of SKCM patients.
Given the fundamental role of OS in SKCM metastasis and progression (Obrador et al., 2019), we also detected the relationship between the clinical factors and calculated risk score. The results suggested that our risk model was able to estimate the metastasis and T stage of patients with SKCM, highlighting its high correlation with cancer prognosis and progression.

Nonetheless, there are some limitations in this study. First, this study was designed as a retrospective analysis; more prospective research should be performed to verify our results. Second, our results lack in vitro or in vivo exploration to confirm the reliability of our mechanism analysis. Therefore, we need to conduct several further experiments to prove the mechanistic connections between these genes and SKCM.

CONCLUSION

In conclusion, we systematically studied prognosis-associated OS genes for SKCM using a series of bioinformatics techniques and identified 16 hub genes that were correlated with overall survival rate. We also successfully developed and validated a prognostic risk model for melanoma using OS genes. Overall, this result may help to study the progression and metastasis of SKCM more thoroughly and provide a deeper understanding of the mechanisms involved in these processes.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This study was supported by the Guangxi Key Research and Development Plan (Grant No. GuikeAD19254003), and the Guangxi Science and Technology Base and Talent Special Project (Grant No. GuikeAD17129012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
Guangxi Key Research and Development Plan: GuikeAD19254003.
Guangxi Science and Technology Base and Talent Special Project: GuikeAD17129012.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
• Yu Yang conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
• Xuan Long, Kun Li, Guiyun Li and Xiaohong Yu performed the experiments, prepared figures and/or tables, and approved the final draft.
• Ping Wen analyzed the data, prepared figures and/or tables, and approved the final draft.
• Jun Luo, Xiaobin Tian and Jinmin Zhao analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
Data Availability

The following information was supplied regarding data availability:

All gene expression profiles are available from the TCGA (https://portal.gdc.cancer.gov; search term: cases.primary_site in ["skin"] and cases.project.program.name in ["TCGA"] and cases.project.project_id in ["TCGA-SKCM"] and files.analysis.workflow_type in ["HTSeq-FPKM"] and files.data_category in ["transcriptome profiling"] and files.data_type in ["Gene Expression Quantification"] and files.experimental_strategy in ["RNA-Seq"], UCSC Xena, (https://xenabrowser.net/datapages/?dataset=TCGA-SKCM.htseq_fpkms.tsv&host=https%3A%2F%2Fgdc.xenahubs.net&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443), GTEx (https://xenabrowser.net/datapages/?dataset=gtex_RSEM_gene_fpkms&host=https%3A%2F%2Ftoil.xenahubs.net&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443) and GSE65904.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.11258#supplemental-information.

REFERENCES

Almeida M, Porter RM. 2019. Sirtuins and FoxOs in osteoporosis and osteoarthritis. *Bone* 121:284–292 DOI 10.1016/j.bone.2019.01.018.

Bader GD, Hogue CWV. 2003. An automated method for finding molecular complexes in large protein interaction networks. *BMC Bioinformatics* 4:2.

Boyé K, Pujol N, Alves ID, Chen YP, Daubon T, Lee YZ, Dedieu S, Constantin M, Bello L, Rossi M, Bjerkvig R, Sue SC, Bikfalvi A, Billottet C. 2017. The role of CXCR3/LRP1 cross-talk in the invasion of primary brain tumors. *Nature Communications* 8:1571 DOI 10.1038/s41467-017-01686-y.

Buendia I, Michalska P, Navarro E, Gameiro I, Egea J, León R. 2016. Nrf2-ARE pathway: an emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. *Pharmacology & Therapeutics* 157:84–104 DOI 10.1016/j.pharmthera.2015.11.003.

Da Silva JM, Moreira Dos Santos TP, Sobral LM, Queiroz-Junior CM, Rachid MA, Proudfoot AEI, Garlet GP, Batista AC, Teixeira MM, Leopoldino AM, Russo RC, Silva TA. 2017. Relevance of CCL3/CCR5 axis in oral carcinogenesis. *Oncotarget* 8:51024–51036 DOI 10.18632/oncotarget.16882.

Du C, Lv Z, Cao L, Ding C, Gyabaah OA, Xie H, Zhou L, Wu J, Zheng S. 2014. MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2. *Journal of Translational Medicine* 12:259 DOI 10.1186/s12967-014-0259-1.

Du XY, Liu X, Wang ZJ, Wang YY. 2017. SLPI promotes the gastric cancer growth and metastasis by regulating the expression of P53, Bcl-2 and Caspase-8. *European Review for Medical and Pharmacological Sciences* 21:1495–1501.

Yang et al. (2021), *PeerJ*, DOI 10.7717/peerj.11258
Eisenstein A, Gonzalez EC, Raghunathan R, Xu X, Wu M, McLean EO, McGee J, Ryu B, Alani RM. 2018. Emerging biomarkers in cutaneous Melanoma. *Molecular Diagnosis & Therapy* 22:203–218 DOI 10.1007/s40291-018-0318-z.

Ekwueme DU, Guy GP, Li C, Rim SH, Parelkar P, Chen SC. 2011. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity—United States, 2000 to 2006. *Journal of the American Academy of Dermatology* 65:S133–S143 DOI 10.1016/j.jaad.2011.04.036.

Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, Diehn M, West RB, Plevritis SK, Alizadeh AA. 2015. The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nature Medicine* 21:938–945 DOI 10.1038/nm.3909.

Gilchrest BA, Eller MS, Geller AC, Yaar M. 1999. The pathogenesis of melanoma induced by ultraviolet radiation. *New England Journal of Medicine* 340:1341–1348 DOI 10.1056/nejm199904293401707.

Gill JG, Piskounova E, Morrison SJ. 2016. Cancer, oxidative stress, and metastasis. *Cold Spring Harbor Symposia on Quantitative Biology* 81:163–175 DOI 10.1101/sqb.2016.81.030791.

Hamm C, Verma S, Petrella T, Bak K, Charette M. 2008. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. *Cancer Treatment Reviews* 34:145–156 DOI 10.1016/j.ctrv.2007.10.003.

Hawkes JE, Truong A, Meyer LJ. 2016. Genetic predisposition to melanoma. *Seminars in Oncology* 43:591–597 DOI 10.1053/j.seminoncol.2016.08.003.

Holmes D. 2014. The cancer that rises with the sun. *Nature* 515:S110–S111 DOI 10.1038/515S110a.

Huang DW, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nature Protocols* 4:44–57 DOI 10.1038/nprot.2008.211.

Human Genomics. 2015. The Genotype-Tissue Expression (GTEx) pilot analysis: multi-tissue gene regulation in humans. *Science* 348:648–660 DOI 10.1126/science.1262110.

Kanavy HE, Gerstenblith MR. 2011. Ultraviolet radiation and melanoma. *Seminars in Cutaneous Medicine and Surgery* 30:222–228 DOI 10.1016/j.sder.2011.08.003.

Klaunig JE. 2018. Oxidative stress and cancer. *Current Pharmaceutical Design* 24:4771–4778 DOI 10.2174/1381612825666190215121712.

Kruk J, Aboul-Enein HY. 2017. Reactive oxygen and nitrogen species in carcinogenesis: implications of oxidative stress on the progression and development of several cancer types. *Mini-Reviews in Medicinal Chemistry* 17:904–919 DOI 10.2174/1389557517666170228115324.

Li C, Wang J, Zhang H, Zhu M, Chen F, Hu Y, Liu H, Zhu H. 2014. Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma. *OncoTarget* 5:8429–8441 DOI 10.18632/oncotarget.2316.

Li W, Gao L-N, Song P-P, You C-G. 2020. Development and validation of a RNA binding protein-associated prognostic model for lung adenocarcinoma. *Aging* 12:3558–3573 DOI 10.18632/aging.102828.
Liu-Smith F, Dellinger R, Meyskens FL. 2014. Updates of reactive oxygen species in melanoma etiology and progression. *Archives of Biochemistry and Biophysics* 563:51–55 DOI 10.1016/j.abb.2014.04.007.

Liu-Smith F, Jia J, Zheng Y. 2017. UV-induced molecular signaling differences in melanoma and non-melanoma skin cancer. *Advances in Experimental Medicine and Biology* 996:27–40 DOI 10.1007/978-3-319-56017-5_3.

Lü J-M, Lin PH, Yao Q, Chen C. 2010. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. *Journal of Cellular and Molecular Medicine* 14:840–860 DOI 10.1111/j.1582-4934.2009.00897.x.

Moloney JN, Cotter TG. 2018. ROS signalling in the biology of cancer. *Seminars in Cell & Developmental Biology* 80:50–64 DOI 10.1016/j.semcdb.2017.05.023.

Obrador E, Liu-Smith F, Dellinger RW, Salvador R, Meyskens FL, Estrela JM. 2019. Oxidative stress and antioxidants in the pathophysiology of malignant melanoma. *Biological Chemistry* 400:589–612 DOI 10.1515/hsz-2018-0327.

PDQATE Board. 2002. Melanoma Treatment (PDQ®): Health Professional Version. In: *PDQ cancer information summaries*. Bethesda: National Cancer Institute (US).

Pedro NF, Biselli JM, Maniglia JV, Santi-Neto D, Pavarino ÉC, Goloni-Bertollo EM, Biselli-Chicote PM. 2018. Candidate biomarkers for oral squamous cell carcinoma: differential expression of oxidative stress-related genes. *Asian Pacific Journal of Cancer Prevention* 19:1343–1349 DOI 10.22034/apjcp.2018.19.5.1343.

Sahin E, Madendag Y, Sahin ME, Madendag IC, Acmaiz G, Karakukcu C, Karaman H, Muderris II. 2018. Cervical local immune response for high-risk human papillomavirus infection: involvement with cervical mucus slpi proteins. *Cancer Control* 25:1073274818798598 DOI 10.1177/1073274818798598.

Suarez-Carmona M, Caherentong P, Kather JN, Rothenheber R, Ahmed A, Berthel A, Heinzelmann A, Moraleda R, Valous NA, Kosaloglu Z, Eurich R, Wolf J, Grauling-Halama S, Hundemer M, Lasitschka F, Klupp F, Kahlert C, Ulrich A, Schneider M, Falk C, Jäger D, Zoernig I, Halama N. 2019. CCR5 status and metastatic progression in colorectal cancer. *Oncoimmunology* 8:e1626193 DOI 10.1080/2162402x.2019.1626193.

Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, Sober AJ, Thompson JA, Wisco OJ, Wyatt S, Hu S, Lamia T. 2019. Guidelines of care for the management of primary cutaneous melanoma. *Journal of the American Academy of Dermatology* 80:208–250 DOI 10.1016/j.jaad.2018.08.055.

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering CV. 2019. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Research* 47:D607–D613 DOI 10.1093/nar/gky1131.

Thomson A, Hemphill D, Jeejeebhoy KN. 1998. Oxidative stress and antioxidants in intestinal disease. *Digestive Diseases* 16:152–158 DOI 10.1159/000016859.
Thul PJ, Åkesson L, Mahdessian D, Geladaki A, Ait Blal H, Alm T, Asplund A, Björk L, Breckels LM, Bäckström A, Danielsson F, Fagerberg L, Fall J, Gatto L, Gnann C, Hober S, Hjelmare M, Johansson F, Lee S, Lindskog C, Mulder J, Mulvey CM, Nilsson P, Oksvold P, Rockberg J, Schutten R, Schwenk JM, Å Sivertsson, Sjöstedt E, Skogs M, Stadler C, Sullivan DP, Tegel H, Winsnes C, Zhang C, Zwahlen M, Mardinoglu A, Pontén F, von Feilitzen K, Lilley KS, Uhlén M, Lundberg E. 2017. A subcellular map of the human proteome. *Science* **356**:eaal3321 DOI 10.1126/science.aal3321.

Tong HV, Hoan NX, Binh MT, Quyen DT, Meyer CG, Hang DTT, Hang DTD, Son HA, Luong HVan, Thuan ND, Giang NT, Quyet D, Bang MH, Song LH, Velavan TP, Toan NL. 2020. Upregulation of Enzymes involved in ISGylation and Ubiquitination in patients with hepatocellular carcinoma. *International Journal of Medical Sciences* 17:347–353 DOI 10.7150/ijms.39823.

Wang JY, Liu GZ, Wilmott JS, La T, Feng YC, Yari H, Yan XG, Thorne RF, Scolyer RA, Zhang XD, Jin L. 2017. Skp2-mediated stabilization of mth1 promotes survival of melanoma cells upon oxidative stress. *Cancer Research* **77**:6226–6239 DOI 10.1158/0008-5472.CAN-17-1965.

Wang SQ, Cui SX, Qu XJ. 2019. Metformin inhibited colitis and colitis-associated cancer (CAC) through protecting mitochondrial structures of colorectal epithelial cells in mice. *Cancer Biology & Therapy* **20**:338–348 DOI 10.1080/15384047.2018.1529108.

Zhou F, Shen Q, Claret FX. 2013. Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. *Journal of Leukocyte Biology* **94**:423–429 DOI 10.1189/jlb.0113006.